Mereo BioPharma Group plc - ROE
MREO
Price:
$0.3094
Market Cap:
$49.39M
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acuma...[Read more]
Industry
Biotechnology
IPO Date
2019-04-24
Stock Exchange
NASDAQ
Ticker
MREO
PE Ratio
[-1.63]
ROE
[-81.25%]
Current Ratio
[6.48]
Dividend Yield
[0%]
Enterprise Value
[13.16M]
Dividend History
The ROE as of June 2026 (TTM) for Mereo BioPharma Group plc (MREO) is -81.25%
According to Mereo BioPharma Group plc’s latest financial reports and current stock price. The company's current ROE is -81.25%. This represents a change of 307.71% compared to the average of -19.93% of the last 4 quarters.
Mereo BioPharma Group plc (MREO) Historical ROE (quarterly & annually)
How has MREO ROE performed in the past?
The mean historical ROE of Mereo BioPharma Group plc over the last ten years is 44.68%. The current -81.25% ROE has changed -281.86% with respect to the historical average. Over the past ten years (40 quarters), MREO's ROE was at its highest in in the December 2020 quarter at 130.28%. The ROE was at its lowest in in the June 2020 quarter at -257.03%.
Average
44.68%
Median
-66.52%
Minimum
-102.35%
Maximum
1.02%
Mereo BioPharma Group plc (MREO) ROE by Quarter and Year
Discovering the peaks and valleys of Mereo BioPharma Group plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 73.35%
Maximum Annual ROE = 1.02%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -102.35%
| Year | ROE | Change |
|---|---|---|
| 2025 | -102.35% | 44.27% |
| 2024 | -70.94% | 21.67% |
| 2023 | -58.31% | -28.85% |
| 2022 | -81.95% | -667.84% |
| 2021 | 14.43% | -98.59% |
| 2020 | 1.02% | -1329.53% |
| 2019 | -83.36% | -14.71% |
| 2018 | -97.74% | 57.40% |
| 2017 | -62.09% | 73.35% |
| 2016 | -35.82% | -Infinity% |
Mereo BioPharma Group plc (MREO) Average ROE
How has MREO ROE performed in the past?
The current ROE of Mereo BioPharma Group plc (MREO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-77.20%
5-year avg
-59.82%
10-year avg
44.68%
Mereo BioPharma Group plc (MREO) ROE vs. Peers
How is MREO’s ROE compared to its peers?
Mereo BioPharma Group plc’s ROE is greater than Candel Therapeutics, Inc. (-60.42%), greater than Contineum Therapeutics, Inc. Class A Common Stock (-27.09%), greater than Aldeyra Therapeutics, Inc. (-57.34%), greater than Kyverna Therapeutics, Inc. (-81.87%), greater than Immutep Limited (-69.20%), greater than ProQR Therapeutics N.V. (-86.47%), greater than Lexeo Therapeutics, Inc. Common Stock (-47.48%), greater than Silence Therapeutics plc (-121.71%), greater than AC Immune S.A. (-123.98%), greater than Capricor Therapeutics, Inc. (-59.27%),
| Company | ROE | Market cap |
|---|---|---|
| -60.42% | $456.23M | |
| -27.09% | $446.39M | |
| -57.34% | $118.23M | |
| -81.87% | $353.40M | |
| -69.20% | $55.15M | |
| -86.47% | $199.13M | |
| -47.48% | $387.11M | |
| -121.71% | $327.33M | |
| -123.98% | $244.26M | |
| -59.27% | $1.30B |
Build a custom stock screener for Mereo BioPharma Group plc (MREO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mereo BioPharma Group plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Mereo BioPharma Group plc (MREO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Mereo BioPharma Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Mereo BioPharma Group plc's ROE?
How is the ROE calculated for Mereo BioPharma Group plc (MREO)?
What is the highest ROE for Mereo BioPharma Group plc (MREO)?
What is the 3-year average ROE for Mereo BioPharma Group plc (MREO)?
What is the 5-year average ROE for Mereo BioPharma Group plc (MREO)?
How does the current ROE for Mereo BioPharma Group plc (MREO) compare to its historical average?